Melanoma molecular classes and prognosis in the postgenomic era

The Lancet Oncology

Volumn 13, Issue 5, 2012, Pages

  Tremante, Elisa ^a   Ginebri, Agnese ^b   Lo Monaco, Elisa ^a   Frascione, Pasquale ^b   Di Filippo, Franco ^a   Terrenato, Irene ^a   Benevolo, Maria ^a   Mottolese, Marcella ^a   Pescarmona, Edoardo ^a   Visca, Paolo ^a   Natali, Pier Giorgio ^a,c   Giacomini, Patrizio ^a  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^b SAN GALLICANO DERMATOLOGICAL INSTITUTE   (Italy)

^c UNIVERSITY OF CHIETI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MICRORNA; OSTEOPONTIN; TRANSCRIPTOME;

BRAF GENE; BRMS1 GENE; CANCER GROWTH; CANCER PROGNOSIS; CANCER STAGING; CANCER STEM CELL; CANCER SURVIVAL; CELL DIFFERENTIATION; CELL RENEWAL; CHROMOSOME ABERRATION; CLINICAL FEATURE; CUTANEOUS MELANOMA; DISEASE ACTIVITY; FOLLOW UP; GENE EXPRESSION PROFILING; GENEALOGY; GENETIC ASSOCIATION; GENETIC HETEROGENEITY; GENOME ANALYSIS; GENOMICS; HUMAN; MALIGNANT TRANSFORMATION; MCAM GENE; MELANOCYTE; MICROARRAY ANALYSIS; MOLECULAR PATHOLOGY; NRAS GENE; ONCOGENE; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; PTEN GENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; RNA FINGERPRINTING; RUNX3 GENE; SEQUENCE ANALYSIS;

GENE EXPRESSION PROFILING; HUMANS; MELANOMA; PROGNOSIS; SKIN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84860424628     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(12)70003-7     Document Type: Review

References (66)

1. Balch CM, Gershenwald JE, Soong SJ, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009, 27:6199-6206.
2. Gimotty PA, Guerry D Prognostication in thin cutaneous melanomas. Arch Pathol Lab Med 2010, 134:1758-1763.
3. Duncan LM The classification of cutaneous melanoma. Hematol Oncol Clin North Am 2009, 23:501-513.
4. Gould Rothberg BE, Bracken MB, Rimm DL Tissue biomarkers for prognosis in cutaneous melanoma: a systematic review and meta-analysis. J Natl Cancer Inst 2009, 101:452-474.
5. Gould Rothberg BE, Rimm DL Biomarkers: the useful and the not so useful-an assessment of molecular prognostic markers for cutaneous melanoma. J Invest Dermatol 2010, 130:1971-1987.
6. Hoek KS DNA microarray analyses of melanoma gene expression: a decade in the mines. Pigment Cell Res 2007, 20:466-484.
7. Nambiar S, Mirmohammadsadegh A, Hengge UR Cutaneous melanoma: fishing with chips. Curr Mol Med 2008, 8:235-243.
8. Hoek KS Exploring melanoma's massively parallel universe. Pigment Cell Melanoma Res 2010, 23:306-307.
9. Bennett DC How to make a melanoma: what do we know of the primary clonal events?. Pigment Cell Melanoma Res 2008, 21:27-38.
10. Melanoma molecular profile Melanoma Molecular Map Project, (accessed March 20, 2012). http://www.mmmp.org/MMMP/public/melanomamolecolarprofile/listMelanoma.mmmp.
11. Mandruzzato S, Callegaro A, Turcatel G, et al. A gene expression signature associated with survival in metastatic melanoma. J Transl Med 2006, 4:50.
12. Winnepenninckx V, Lazar V, Michiels S, et al. Gene expression profiling of primary cutaneous melanoma and clinical outcome. J Natl Cancer Inst 2006, 98:472-482.
13. Alonso SR, Tracey L, Ortiz P, et al. A high-throughput study in melanoma identifies epithelial-mesenchymal transition as a major determinant of metastasis. Cancer Res 2007, 67:3450-3460.
14. Soikkeli J, Lukk M, Nummela P, et al. Systematic search for the best gene expression markers for melanoma micrometastasis detection. J Pathol 2007, 213:180-189.
15. Brunner G, Reitz M, Schwipper V, et al. Increased expression of the tumor suppressor PLZF is a continuous predictor of long-term survival in malignant melanoma patients. Cancer Biother Radiopharm 2008, 23:451-459.
16. John T, Black MA, Toro TT, et al. Predicting clinical outcome through molecular profiling in stage III melanoma. Clin Cancer Res 2008, 14:5173-5180.
17. Kauffmann A, Rosselli F, Lazar V, et al. High expression of DNA repair pathways is associated with metastasis in melanoma patients. Oncogene 2008, 27:565-573.
18. Bogunovic D, O'Neill DW, Belitskaya-Levy I, et al. Immune profile and mitotic index of metastatic melanoma lesions enhance clinical staging in predicting patient survival. Proc Natl Acad Sci USA 2009, 106:20429-20434.
19. Conway C, Mitra A, Jewell R, et al. Gene expression profiling of paraffin-embedded primary melanoma using the DASL assay identifies increased osteopontin expression as predictive of reduced relapse-free survival. Clin Cancer Res 2009, 15:6939-6946.
20. Haqq C, Nosrati M, Sudilovsky D, et al. The gene expression signatures of melanoma progression. Proc Natl Acad Sci USA 2005, 102:6092-6097.
21. Kashani-Sabet M, Venna S, Nosrati M, et al. A multimarker prognostic assay for primary cutaneous melanoma. Clin Cancer Res 2009, 15:6987-6992.
22. Caramuta S, Egyházi S, Rodolfo M, et al. MicroRNA expression profiles associated with mutational status and survival in malignant melanoma. J Invest Dermatol 2010, 130:2062-2070.
23. Segura MF, Belitskaya-Levy I, Rose AE, et al. Melanoma microRNA signature predicts post-recurrence survival. Clin Cancer Res 2010, 16:1577-1586.
24. Mauerer A, Roesch A, Hafner C, et al. Identification of new genes associated with melanoma. Exp Dermatol 2011, 20:502-507.
25. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM REporting recommendations for tumour MARKer prognostic studies (REMARK). Br J Cancer 2005, 93:387-391.
26. Desmedt C, Sotiriou C, Piccart-Gebhart MJ Development and validation of gene expression profile signatures in early-stage breast cancer. Cancer Invest 2009, 27:1-10.
27. Weigelt B, Baehner FL, Reis-Filho JS The contribution of gene expression profiling to breast cancer classification, prognostication and prediction: a retrospective of the last decade. J Pathol 2010, 220:263-280.
28. Cianfrocca M, Gradishar W New molecular classifications of breast cancer. CA Cancer J Clin 2009, 59:303-313.
29. Correa Geyer F, Reis-Filho J Microarray-based gene expression profiling as a clinical tool for breast cancer management: are we there yet?. Int J Surg Pathol 2009, 17:285-302.
30. Sotiriou C, Pusztai L Gene-expression signatures in breast cancer. N Engl J Med 2009, 360:790-800.
31. Yeoh EJ, Ross ME, Shurtleff SA, et al. Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. Cancer Cell 2002, 1:133-143.
32. Yong AS, Melo JV The impact of gene profiling in chronic myeloid leukaemia. Best Pract Res Clin Haematol 2009, 22:181-190.
33. Bacher U, Kohlmann A, Haferlach T Current status of gene expression profiling in the diagnosis and management of acute leukaemia. Br J Haematol 2009, 145:555-568.
34. Iqbal J, Liu Z, Deffenbacher K, Chan WC Gene expression profiling in lymphoma diagnosis and management. Best Pract Res Clin Haematol 2009, 22:191-210.
35. Wouters BJ, Lowenberg B, Delwel R A decade of genome-wide gene expression profiling in acute myeloid leukemia: flashback and prospects. Blood 2009, 113:291-298.
36. Brocker EB, Suter L, Sorg C HLA-DR antigen expression in primary melanomas of the skin. J Invest Dermatol 1984, 82:244-247.
37. D'Alessandro G, Zardawi I, Grace J, McCarthy WH, Hersey P Immunohistological evaluation of MHC class I and II antigen expression on nevi and melanoma: relation to biology of melanoma. Pathology 1987, 19:339-346.
38. van Duinen SG, Ruiter DJ, Broecker EB, et al. Level of HLA antigens in locoregional metastases and clinical course of the disease in patients with melanoma. Cancer Res 1988, 48:1019-1025.
39. Zaloudik J, Moore M, Ghosh AK, Mechl Z, Rejthar A DNA content and MHC class II antigen expression in malignant melanoma: clinical course. J Clin Pathol 1988, 41:1078-1084.
40. Colloby PS, West KP, Fletcher A Is poor prognosis really related to HLA-DR expression by malignant melanoma cells?. Histopathology 1992, 20:411-416.
41. Ostmeier H, Fuchs B, Otto F, et al. Prognostic immunohistochemical markers of primary human melanomas. Br J Dermatol 2001, 145:203-209.
42. Piras F, Colombari R, Minerba L, et al. The predictive value of CD8, CD4, CD68, and human leukocyte antigen-D-related cells in the prognosis of cutaneous malignant melanoma with vertical growth phase. Cancer 2005, 104:1246-1254.
43. Fan C, Oh DS, Wessels L, et al. Concordance among gene-expression-based predictors for breast cancer. N Engl J Med 2006, 355:560-569.
44. Meyerson M, Gabriel S, Getz G Advances in understanding cancer genomes through second-generation sequencing. Nat Rev Genet 2010, 11:685-696.
45. Tsao H, Cosimi AB, Sober AJ Ultra-late recurrence (15 years or longer) of cutaneous melanoma. Cancer 1997, 79:2361-2370.
46. Pacifico MD, Grover R, Richman PI, Daley FM, Buffa F, Wilson GD Development of a tissue array for primary melanoma with long-term follow-up: discovering melanoma cell adhesion molecule as an important prognostic marker. Plast Reconstr Surg 2005, 115:367-375.
47. Zhang Z, Chen G, Cheng Y, Martinka M, Li G Prognostic significance of RUNX3 expression in human melanoma. Cancer 2011, 117:2719-2727.
48. Li J, Cheng Y, Tai D, Martinka M, Welch DR, Li G Prognostic significance of BRMS1 expression in human melanoma and its role in tumor angiogenesis. Oncogene 2011, 30:896-906.
49. Devitt B, Liu W, Salemi R, et al. Clinical outcome and pathological features associated with NRAS mutation in cutaneous melanoma. Pigment Cell Melanoma Res 2011, 24:666-672.
50. Wei X, Walia V, Lin JC, et al. Exome sequencing identifies GRIN2A as frequently mutated in melanoma. Nat Genet 2011, 43:442-446.
51. Garraway LA, Widlund HR, Rubin MA, et al. Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature 2005, 436:117-122.
52. Berger MF, Levin JZ, Vijayendran K, et al. Integrative analysis of the melanoma transcriptome. Genome Res 2010, 20:413-427.
53. Pleasance ED, Cheetham RK, Stephens PJ, et al. A comprehensive catalogue of somatic mutations from a human cancer genome. Nature 2010, 463:191-196.
54. Onken MD, Worley LA, Ehlers JP, Harbour JW Gene expression profiling in uveal melanoma reveals two molecular classes and predicts metastatic death. Cancer Res 2004, 64:7205-7209.
55. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010, 363:711-723.
56. Flaherty KT, Puzanov I, Kim KB, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010, 363:809-819.
57. Romano E, Schwartz GK, Chapman PB, Wolchock JD, Carvajal RD Treatment implications of the emerging molecular classification system for melanoma. Lancet Oncol 2011, 12:913-922.
58. Tseng JR, Stuart D, Aardalen K, et al. Use of DNA microarray and small animal positron emission tomography in preclinical drug evaluation of RAF265, a novel B-Raf/VEGFR-2 inhibitor. Neoplasia 2011, 13:266-275.
59. Mischiati C, Natali PG, Sereni A, et al. cDNA array profiling of melanomas and paired melanocyte cultures. J Cell Physiol 2006, 207:697-705.
60. Houghton AN, Eisinger M, Albino AP, Cairncross JG, Old LJ Surface antigens of melanocytes and melanomas. Markers of melanocyte differentiation and melanoma subsets. J Exp Med 1982, 156:1755-1766.
61. Gupta PB, Kuperwasser C, Brunet JP, et al. The melanocyte differentiation program predisposes to metastasis after neoplastic transformation. Nat Genet 2005, 37:1047-1054.
62. Adameyko I, Lallemend F, Aquino JB, et al. Schwann cell precursors from nerve innervation are a cellular origin of melanocytes in skin. Cell 2009, 139:366-379.
63. Boiko AD, Razorenova OV, van de Rijn M, et al. Human melanoma-initiating cells express neural crest nerve growth factor receptor CD271. Nature 2010, 466:133-137.
64. Taghizadeh R, Noh M, Huh YH, et al. CXCR6, a newly defined biomarker of tissue-specific stem cell asymmetric self-renewal, identifies more aggressive human melanoma cancer stem cells. PLoS One 2010, 5:e15183.
65. Rambow F, Larue L The quest for the melanoma stem cell: still more questions than answers. Pigment Cell Melanoma Res 2010, 23:307-309.
66. Grichnik JM, Ali WN, Burch JA, et al. KIT expression reveals a population of precursor melanocytes in human skin. J Invest Dermatol 1996, 106:967-971.